ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i5.1163ppharm-50Research ArticleЛЕКЦИЯLECTUREСРЕДСТВА ДОСТАВКИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ ПРИ ИНГАЛЯЦИОННОЙ ТЕРАПИИ У ДЕТЕЙ: КРИТЕРИИ ВЫБОРАMEANS OF DRUG DELIVERY IN THE EVENT OF INHALATION THERAPY IN CHILDREN: SELECTION CRITERIAСелимзяноваЛ. Р.SelimzyanovaL. R.

кандидат медицинских наук, старший научный сотрудник отдела стандартизации и клинической фармакологии Научного центра здоровья детей, ассистент кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова Адрес: 119991, Москва, Ломоносовский проспект, д. 2, стр. 1, тел.: +7 (495) 967-14-65

Selimzyanova@nczd.ruВишнёваЕ. А.VishnevaE. A.vishneva@nczd.ruПромысловаЕ. А.PromyslovaE. A.vishneva@nczd.ruНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской ФедерацииРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian FederationНаучный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian Federation201401102014115Педиатрическая фармакология4044Copyright © Селимзянова Л.Р., Вишнёва Е.А., Промыслова Е.А., 20142014Селимзянова Л.Р., Вишнёва Е.А., Промыслова Е.А.Selimzyanova L.R., Vishneva E.A., Promyslova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/50

Ингаляционная терапия как способ доставки лекарственных препаратов ― ключевой аспект терапии респираторных заболеваний у детей, который играет важную роль в достижении контроля над бронхиальной астмой. Для достижения оптимального клинического эффекта необходим тщательный подбор устройства для ингаляции с учетом особенностей лекарственного препарата, возраста ребенка, тяжести его состояния, когнитивных способностей пациента и возможностей родителей, а также с учетом клинических рекомендаций по соответствующим заболеваниям. Для обеспечения приверженности рекомендациям немаловажно использовать индивидуальный подход и учитывать предпочтения пациента. Одним из основополагающих условий эффективной ингаляционной терапии является четкое разъяснение доктором техники ингаляции и ухода за прибором, а также регулярный врачебный контроль за соблюдением данных инструкций пациентом и его родителями. В статье представлен алгоритм выбора устройства доставки ингаляционного препарата для использования у детей, а также обзор ингаляторов, существующих в настоящее время, их достоинства и недостатки.

 

Inhalation therapy as means of drug delivery is a key aspect of therapy of respiratory diseases in children, which plays an important role in achieving control over bronchial asthma. Optimal clinical effect requires comprehensive selection of inhalation devices given the drug’s peculiarities, the child’s age, severity of his/her condition, the patient’s cognitive potential and capabilities of his/her parents, as well as clinical recommendations on the corresponding diseases. It is rather important to observe individual approach and the patient’s preferences in order to ensure adherence to the recommendations. One of the crucial conditions of effective inhalation therapy is a clear explanation of the inhalation technique and device maintenance by the doctor, as well as regular medical control over observation of the given instructions by the patient and his/her parents. The article presents an algorithm of selecting means of inhalation drug delivery for use in children and the review of currently marketed inhalers, their advantages and drawbacks.

 

детиингаляционная терапияастмадозированные аэрозольные ингаляторыдозированные порошковые ингаляторынебулайзерыизихейлерchildreninhalation therapyasthmametered aerosol inhalersmetered powder inhalersnebulizersEasyhalerReferencesPaediatric Respiratory Medicine ERS Handbook 1st Edition Editors Ernst Eber. Fabio Midulla 2013. European Respiratory Society. 2013. 719 р.Paediatric Respiratory Medicine ERS Handbook 1st Edition Editors Ernst Eber. Fabio Midulla 2013. European Respiratory Society. 2013. 719 р.Labiris N. R., Dolovich M. B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aero so-lized medications. Br J Clin Pharmacol. 2003; 56 (6): 588–99.Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003; 56 (6): 588−99.Намазова-Баранова Л. С., Алексеева А. А., Алтунин В. В., Анто-нова Е. В., Аршба Э. А., Ахмедуллина Д. И., Бакрадзе М. Д., Баранов А. А., Ботвиньева В. В., Важнова И. М., Вишнёва Е. А., Вознесенская Н. И., Волков К. С., Галицкая М. Г., Гайворонская А. Г., Геворкян А. К., Горячкина Л. А., Деев И. А., Дворяковский И. В., Дмитриенко Е. Г. и др. Аллергия у детей: от теории к практике. Под ред. Л. С. Намазовой-Барановой. Москва. 2011.Namazova-Baranova L.S., Alekseeva A.A., Altunin V.V., Antonova E.V., Arshba E.A., Akhmedullina D.I., Bakradze M.D., Baranov A.A., Botvin'eva V.V., Vazhnova I.M., Vishneva E.A., Voznesenskaya N.I., Volkov K.S., Galitskaya M.G., Gaivoronskaya A.G., Gevorkyan A.K., Goryachkina L.A., Deev I.A., Dvoryakovskii I.V., Dmitrienko E.G. et al. Allergiya u detei: ot teorii k praktike. Pod red. L.S. Namazovoi-Baranovoi [Allergies in Children: from Theory to Practice. Edited by L.S. Namazova-Baranova]. Moscow, 2011.Селимзянова Л. Р., Промыслова Е. А., Вишнёва Е. А. Ингаляционная терапия у детей: проблемы и решения. Вопросы современной педиатрии. 2014; 13 (2): 89–94.Selimzyanova L.R., Promyslova E.A., Vishneva E.A. Inhalation therapy in children: problems and solutions. Voprosy sovremennoi pediatrii = Current Pediatrics. 2014; 13 (2): 89−94.Вишнёва Е. А., Намазова-Баранова Л. С. Бронхиальная астма у детей младше 8 лет: как снизить частоту обострений и госпитализаций? Педиатрическая фармакология. 2009; 6 (1): 51–54.Vishneva E.A., Namazova-Baranova L.S. Bronchial asthma in children younger than 8 years: how to reduce the frequency of exacerbations and hospitalizations? Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009; 6 (1): 51−54.Brocklebank D., Ram F., Wright J., Barry P., Cates C., Davies L., Douglas G., Muers M., Smith D., White J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the literature. Health Technol Assess. 2001; 5 (26): 1–149.Brocklebank D., Ram F., Wright J., Barry P., Cates C., Davies L., Douglas G., Muers M., Smith D., White J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the literature. Health Technol Assess. 2001; 5 (26): 1−149.Dolovich M. B., Ahrens R. C., Hess D. R., Anderson P., Dhand R., Rau J. L., Smaldone G. C., Guyatt G. American College of Chest Physicians; American College of Asthma, Allergy and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127 (1): 335–371.Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., Smaldone G.C., Guyatt G. American College of Chest Physicians; American College of Asthma, Allergy and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127 (1): 335−371.From the Global initiative for asthma management and prevention. 2014 (revision). Available from: http://www.ginasthma.orgFrom the Global initiative for asthma management and prevention. 2014 (revision). Available from: http://www.ginasthma.orgFrom the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger, Global Initiative for Asthma. GINA. 2009. Available from: http://www.ginasthma.org/From the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger, Global Initiative for Asthma. GINA. 2009. Available at: http://www.ginasthma.org/Баранов А. А., Хаитов Р. М. (ред.) Аллергология и иммунология. М., 2011. 256 с.Baranov A.A., Khaitov R.M. (red.) Allergologiya i immunologiya [Allergology and Immunology]. Moscow, 2011. 256 p.Geller D. E. MD. Comparing Clinical Features of the Nebulizer, Metered-Dose Inhaler, and Dry Powder Inhaler. Respiratory Care. 2005, oct. 1; 50 (10): 1313–1322.Geller D.E. MD. Comparing Clinical Features of the Nebulizer, Metered-Dose Inhaler, and Dry Powder Inhaler. Respiratory Care. 2005, oct. 1; 50 (10): 1313−1322.Вишнёва Е. А., Намазова-Баранова Л. С., Алексеева А. А., Эфендиева К. Е., Левина Ю. Г., Вознесенская Н. И., Томилова А. Ю., Селимзянова Л. Р., Промыслова Е. А. Детская астма: ключевые принципы достижения контроля на современном этапе. Педиатрическая фармакология. 2013; 10 (4): 60–72.Vishneva E.A., Namazova-Baranova L.S., Alekseeva A.A., Efendieva K.E., Levina Yu.G., Voznesenskaya N.I., Tomilova A.Yu., Selimzyanova L.R., Promyslova E.A. Pediatric asthma: key principles for achieving control at the present stage. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (4): 60−72.Laube B. L., Janssens H. M., de Jongh F. H. C., Devadason S. G., Dhand R., Diot P., Everard M. L., Horvath I., Navalesi P., Voshaar T., Chrystyn H. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37 (6): 1308–1417.Laube B.L., Janssens H.M., de Jongh F.H.C., Devadason S.G., Dhand R., Diot P., Everard M.L., Horvath I., Navalesi P., Voshaar T., Chrystyn H. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37 (6): 1308−1417.Синопальников А. И., Клячкина И. Л. Средства для доставки лекарств в дыхательные пути при бронхиальной астме. Российские медицинские вести. 2003; 1 (8): 2–7.Sinopal'nikov A.I., Klyachkina I.L. Means for delivery of drugs to the airways in asthma. Rossiiskie meditsinskie vesti = Russian medical news. 2003; 1 (8): 2−7.Вишнёва Е. А., Торшхоева Р. М., Алексеева А. А., Левина Ю. Г., Эфендиева К. Е., Томилова А. Ю., Вознесенская Н. И. Бронхиаль ная астма у детей раннего возраста и дошкольников: особенности базисной терапии. Педиатрическая фармакология. 2011; 8 (3): 70–74.Vishneva E.A., Torshkhoeva R.M., Alekseeva A.A., Levina Yu.G., Efendieva K.E., Tomilova A.Yu., Voznesenskaya N.I. Bronchial asthma in toddlers and preschoolers: features basic therapy. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (3): 70−74.Niven R. W., Ip A. Y., Mittleman S., Prestrelski S. J., Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res. 1995; 12 (1): 53–59.Niven R.W., Ip A.Y., Mittleman S., Prestrelski S.J., Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res. 1995; 12 (1): 53−59.Munster A. M., Benstrup E., Jensen J. I., Gram J. Jet and ultrasonic nebulization of chain urokinase plasminogen activator (scu-PA). J Aerosol Med. 2000; 13 (4): 325–333.Münster A.M., Benstrup E., Jensen J.I., Gram J. Jet and ultrasonic nebulization of chain urokinase plasminogen activator (scu-PA). J Aerosol Med. 2000; 13 (4): 325−333.Nikander K., Turpeinen M., Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med. 1999; 12 (2): 47–53.Nikander K., Turpeinen M., Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med. 1999; 12 (2): 47−53.Boe J., Dennis J. H., O'Driscoll B. R., Bauer T. T., Carone M., Dautzenberg B., Diot P., Heslop K., Lannefors L. European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001 Jul; 18 (1): 228–242.Boe J., Dennis J.H., O'Driscoll B.R., Bauer T.T., Carone M., Dautzenberg B., Diot P., Heslop K., Lannefors L. European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001 Jul; 18 (1): 228−242.Reychler G., Dupont C., Dubus J. C. Disinfection of devices for nebulization: stakes, difficulties, and improvement proposals. Rev Mal Respir. 2007 Dec; 24 (10): 1351–1361.Reychler G., Dupont C., Dubus J.C. Disinfection of devices for nebulization: stakes, difficulties, and improvement proposals. Rev Mal Respir. 2007 Dec; 24 (10): 1351−1361.Brzezinski L. X., Riedi C. A., Kussek P., Souza H. H., Rosario N. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J Bras Pneumol. 2011 May-Jun; 37 (3): 341–347.Brzezinski L.X., Riedi C.A., Kussek P., Souza H.H., Rosário N. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J Bras Pneumol. 2011 May-Jun; 37 (3): 341−347.Bollinger M. E., Butz A., Mudd K., Hamilton R. G. Contamination of nebulizers with environmental allergens. Ann Allergy Asthma Immunol. 2005 Nov; 95 (5): 429–432.Bollinger M.E., Butz A., Mudd K., Hamilton R.G. Contamination of nebulizers with environmental allergens. Ann Allergy Asthma Immunol. 2005 Nov; 95 (5): 429−432.Cates C. J., Crilly J. A., Rowe B. H. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2006; 2: CD000052.Cates C.J., Crilly J.A., Rowe B.H. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2006; 2: CD000052.Quynh Doan C. M., MD, Allan Shefrin, MD., David Johnson, MD. Cost-effectiveness of Metered-Dose Inhalers for Asthma Exacerbations in the Pediatric Emergency Department. Pediatrics. 2011 May 1; 127 (5): e1105–e1111.Quynh Doan C.M., MD, Allan Shefrin, MD., David Johnson, MD. Cost-effectiveness of Metered-Dose Inhalers for Asthma Exacerbations in the Pediatric Emergency Department. Pediatrics. 2011 May 1; 127 (5): e1105−e1111.Lavorini F., Magnan A., Dubus J. C., Voshaar T., Corbetta L., Broeders M., Dekhuijzen R., Sanchis J., Viejo J. L., Barnes P., Cor rigan C., Levy M., Crompton G. K. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008; 102 (4): 593–604.Lavorini F., Magnan A., Dubus J.C., Voshaar T., Corbetta L., Broeders M., Dekhuijzen R., Sanchis J., Viejo J.L., Barnes P., Corrigan C., Levy M., Crompton G.K. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008; 102 (4): 593−604.Pedersen S., Hansen O. R., Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990; 65 (3): 308–10.Pedersen S., Hansen O.R., Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990; 65 (3): 308−10.Poukkula A., Alanko K., Kilpio K., Knuuttila A., Koskinen S., Laitinen J., Lehtonen K., Liippo K., Lindqvist A., Lahelma S., Paananen M., Ruotsalainen E. M., Salomaa E. R., Silvasti M., Suuronen U., Toivanen P., Vilkka V. Comparison of a Multidose Powder Inhaler Containing Beclomethasone Dipropionate (BDP) with a BDP Metered Dose Inhaler with Spacer in the Treatment of Asthmatic Patients. Clin Drug Investig. 1998; 16 (2): 101–110.Poukkula A., Alanko K., Kilpiö K., Knuuttila A., Koskinen S., Laitinen J., Lehtonen K., Liippo K., Lindqvist A., Lähelmä S., Paananen M., Ruotsalainen E.M., Salomaa E.R., Silvasti M., Suuronen U., Toivanen P., Vilkka V. Comparison of a Multidose Powder Inhaler Containing Beclomethasone Dipropionate (BDP) with a BDP Metered Dose Inhaler with Spacer in the Treatment of Asthmatic Patients. Clin Drug Investig. 1998; 16 (2): 101−110.Tukiainen H., Rytila P., Hamalainen K. M., Silvasti M. S., Keski-Karhu J. Finnish Study Group. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med. 2002; 96 (4): 221–229.Tukiainen H., Rytilä P., Hämäläinen K.M., Silvasti M.S., Keski-Karhu J.; Finnish Study Group. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients Respir Med. 2002; 96 (4): 221−229.Ahonen A., Leinonen M., Ranki-Pesonen M. Patient satisfaction with Easyhaler compared with other inhalation systems in the treatment of asthma: a meta-analysis. Curr Ther Res. 2000; 61 (2): 61–73.Ahonen A., Leinonen M., Ranki-Pesonen M. Patient satisfaction with Easyhaler compared with other inhalation systems in the treatment of asthma: a meta-analysis. Curr Ther Res. 2000; 61 (2): 61–73.Vanto T., Hamalainen K. M., Vahteristo M., Wille S., Nja F., Hyldebrandt N. Study Group. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med. 2004; 17 (1): 15–24.Vanto T., Hämäläinen K.M., Vahteristo M., Wille S., Nja F., Hyldebrandt N. Study Group. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med. 2004; 17 (1): 15−24.Galffy G., Mezei G., Nemeth G., Tamasi L., Muller V., Selroos O., Orosz M. Inhaler Competence and Patient Satisfaction with Easyhaler: Results of Two Real-Life Multicentre Studies in Asthma and COPD. Drugs. 2013; 13 (3): 215–222.Gálffy G., Mezei G., Németh G., Tamási L., Müller V., Selroos O., Orosz M. Inhaler Competence and Patient Satisfaction with Easyhaler: Results of Two Real-Life Multicentre Studies in Asthma and COPD. Drugs. 2013; 13 (3): 215–222.Thomas V., Burden A., von Ziegenweidt J., Gould S., Hutton C., Price D. Innovative dry powder inhaler (DPI) shows improved cost-effectiveness compared with current DPIs for asthma therapy in UK primary care ERS 2013 Annual Congress, Barselona Spine 7–11 September. Eur Respir J. 2013; 42 (57): 3833.Thomas V., Burden A., von Ziegenweidt J., Gould S., Hutton C., Price D. Innovative dry powder inhaler (DPI) shows improved cost-effectiveness compared with current DPIs for asthma therapy in UK primary care ERS 2013 Annual Congress, Barselona Spine 7−11 September. Eur Respir J. 2013; 42 (57): 3833.

The authors declare that there are no conflicts of interest present.